Get notified of page updates
Education > XRAY > Search Results

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search by Topic Submit an Article for Review

All XRAYs

151 through 160 of 310

Relevance: Medium-High

Strength of Science: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Study : Inherited mutations in metastatic breast cancer patients

Relevance: Medium-High

Strength of Science: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with metastatic breast cancer

Recent research shows that a significant portion of patients with metastatic breast cancer have harmful mutations in a gene associated with hereditary breast cancer and increased breast cancer risk. (9/26/19)

Read More

Relevance: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Guideline : FDA issues warning on CDK inhibitors

Relevance: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People currently taking a CDK inhibitor

The U.S. Food and Drug Administration issued a safety alert for CDK inhibitors, including Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib). (9/24/19)

Read More

Relevance: Medium-High

Strength of Science: Medium-High

View Related Clinical Trials

Study : Does eating meat affect breast cancer risk?

Relevance: Medium-High

Strength of Science: Medium-High

View Related Clinical Trials

Most relevant for: Women with a family history of breast cancer

Eating meat has been suggested to increase breast cancer risk. The recent Sister Study looked at meat type, cooking methods and breast cancer risk in a study of 42,012 women.  (9/10/19)

Read More

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Is it safe for BRCA mutation carriers to become pregnant following breast cancer?

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Women with a BRCA mutation who are considering pregnancy after breast cancer

New research shows that pregnancy after breast cancer is safe for women with BRCA mutations and their babies. (9/4/19)

Read More

Relevance: High

Strength of Science: Medium

View Related Clinical Trials

Study : Supportive care can improve quality of life for people with metastatic breast cancer

Relevance: High

Strength of Science: Medium

View Related Clinical Trials

Most relevant for: People diagnosed with metastatic breast cancer

Metastatic breast cancer patients have unique needs for treatment and care. Connecting patients to appropriate support services and palliative care is an area of need in health care. A recent study reported improvement in metastatic breast cancer patient quality of life and wellness with an intervention program called the Supportive, Education and Advocacy (MBC-SEA) program. (8/21/19)

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : MRI or mammograms for detecting breast cancer in families with unknown genetic mutations?

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with a personal or family history of cancer where no mutation has been found

MRI and mammograms are used together to detect breast cancer in high-risk women who test positive for a BRCA or other gene mutation that increases the risk for breast cancer. For women with a family history of breast cancer but no known genetic mutation, increased screening is recommended. But what method is best? A recent clinical trial in the Netherlands compared MRI and mammography for this population. (8/15/19)

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Study : Diagnosis and treatment delays in young women with breast cancer

Relevance: Medium-High

Strength of Science: Medium-High

Most relevant for: Young women who find a breast lump and young women newly-diagnosed with breast cancer

Young women are more likely to have delays in a breast cancer diagnosis and treatment.  Factors that affect these delays include pregnancy, breastfeeding, financial concerns and having a family history of breast or ovarian cancer. (8/5/19)

Este artículo está disponible en español.

Read More

Relevance: High

Research Timeline: Post Approval

View Related Clinical Trials

Guideline : FDA asks Allergan to recall certain textured breast implants

Relevance: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Women with, or considering breast reconstruction with implants

On July 25, 2019, the Food and Drug Administration requested that breast implant manufacturer Allergan recall its BIOCELL textured implants and expanders due to an association with a rare type of lymphoma called Breast Implant Associated Anaplastic Large Cell Lymphoma or BIA-ALCL. The FDA does not recommend removing implants for people who do not have disease symptoms. This XRAYS review updates information about this FDA recall. (7/29/19)

Read More

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Study : CDK inhibitors may increase survival for ER-positive metastatic breast cancer patients

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with metastatic, hormone-positive, Her2-negative breast cancer

The phase III MONALEESA-7 study is a clinical trial looking at the effect of a type of treatment known as a CDK4/6 inhibitor in pre- or perimenopausal women with hormone receptor–positive advanced breast cancer. (7/22/19) 

 

 

Read More

Relevance: High

Strength of Science: High

Research Timeline: Human Research

View Related Clinical Trials

Study : Results from the POLO trial: Olaparib may delay cancer progression in metastatic pancreatic cancer patients with BRCA mutations.

Relevance: High

Strength of Science: High

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: People diagnosed with pancreatic cancer who have a BRCA mutation

Note: On 12/27/19, the FDA approved olaparib for treatment of pancreatic cancer in people with a BRCA mutation based on the results of the POLO study.

The POLO clinical trial looks at whether the PARP inhibitor olaparib improves outcomes for those with metastatic pancreatic cancer after platinum-based chemotherapy.  (7/3/19) 

Read More